Use of Combinatorial Pharmacogenomic Guidance in Treating Psychiatric Disorders:financial impact on a health plan

Joachim Benitez, Christina Cool, Dennis J. Scotti

Personalized Medicine · 2018 · 33 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

AIM: To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU). PATIENTS & METHODS: cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods. RESULTS: 205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a per-member-per-month savings of US$0.07. Disease-specific analyses resulted in similar savings. CONCLUSION: Use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations.

References

21